HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.

Maria Serena RocaTania MocciaFederica IannelliCristina TestaCarlo VitaglianoMichele MinopoliRosa CamerlingoGiulia De RisoRossella De CecioFrancesca BruzzeseMariarosaria ConteLucia AltucciElena Di GennaroAntonio AvalloneAlessandra LeoneAlfredo Budillon

Published in: Journal of experimental & clinical cancer research : CR (2022)

Overall, we suggest a novel therapeutic strategy based on domatinostat to improve efficacy and to overcome resistance of commonly used chemotherapeutics in PDAC that warrant further clinical evaluation.

Keyphrases

clinical evaluation
cancer stem cells
locally advanced
histone deacetylase
induced apoptosis
radiation therapy
oxidative stress